The Effect of YiQiFuMai on Ischemic Heart Failure by Improve Myocardial Microcirculation and Increase eNOS and VEGF Expression
- 1 Department of Heart Center, Hebei General Hospital, Shijiazhuang, China
- 2 Department of Heart Center, Hebei General Hospital, Shijiazhuang, China
- 3 Department of Heart Center, Hebei General Hospital, Shijiazhuang, China
- 4 Department of Heart Center, Hebei General Hospital, Shijiazhuang, China
Abstract
Objective: To assess the effects of traditional Chinese medicine YiQiFuMai on cardiac function during the progression of ischemic heart failure. Methods: Rabbits were divided into sham, heart failure, and YiQiFuMai groups. The ischemic heart failure model was established in New Zealand white rabbits, which were intraperitoneally injected with YiQiFuMai injection and 0.9% sodium chloride after the operation. After six weeks, cardiac function was examined by ultrasound; serum BNP levels were measured by ELISA; p-AKT, eNOS, ICAM-1 and VEGF levels were evaluated by real-time PCR and Western-Blot; pathological changes of the myocardial tissue were observed by H&E staining; CD31 expression in tissue samples was analyzed by immunohistochemistry. The ultrastructure and microcirculation of myocardial tissue specimens from the three groups were assessed by transmission electron microscopy. Results: YiQiFuMai decreased serum BNP levels, and increased LVEF and reduced LVEDD at 6 weeks postoperatively. In addition, YiQiFuMai can improve myocardial damage and microcirculation structure, as assessed by histology and transmission electron microscope. At the molecular level, treatment with YiQiFuMai resulted in increased eNOS, VEGF and p-AKT levels but reduced ICAM-1 amounts compared with the heart failure group. Conclusion: Ischemic heart failure damages the microvascular structure and functions of the myocardium. Treatment with YiQiFuMai potentially ameliorates microcirculatory damage and alleviates cardiac failure by improving endothelial function and angiogenesis, and inhibiting inflammatory cell adhesion.
- Redfield, M.M. (2017) Heart Failure with Preserved Ejection Fraction. The New England Journal of Medicine, 376, 897. https://doi.org/10.1056/NEJMc1615918
- Metra, M. and Teerlink, J.R. (2017) Heart Failure. The Lancet, 390, 1981-1995. https://doi.org/10.1016/S0140-6736(17)31071-1
- Sestito, A., et al. (2011) Relation between Cardiovascular Risk Factors and Coronary Microvascular Dysfunction in Cardiac Syndrome X. Journal of Cardiovascular Medicine, 12, 322-327. https://doi.org/10.2459/JCM.0b013e3283406479
- Fleming, I. (2010) Molecular Mechanisms Underlying the Activation of eNOS. Pflügers Archiv, 459, 793-806. https://doi.org/10.1007/s00424-009-0767-7
- Engin, A. (2017) Endothelial Dysfunction in Obesity. Advances in Experimental Medicine and Biology, 960, 345-379. https://doi.org/10.1007/978-3-319-48382-5_15
- Yoo, S.Y. and Kwon, S.M. (2013) Angiogenesis and Its Therapeutic Opportunities. Mediators of Inflammation, 2013, Article ID: 127170. https://doi.org/10.1155/2013/127170
- Koch, S., et al. (2011) Signal Transduction by Vascular Endothelial Growth Factor Receptors. Biochemical Journal, 437, 169-183. https://doi.org/10.1042/BJ20110301
- Greenberg, D.A. and Jin, K. (2013) Vascular Endothelial Growth Factors (VEGFs) and Stroke. Cellular and Molecular Life Sciences, 70, 1753-1761. https://doi.org/10.1007/s00018-013-1282-8
- Li, F., Tan, Y.S., Chen, H.L., Yan, Y., Zhai, K.F., Li, D.P., et al. (2015) Identification of Schisandrin as a Vascular Endothelium Protective Component in YiQiFuMai Powder Injection Using HUVECs Binding and HPLC-DAD-Q-TOF-MS/MS Analysis. Journal of Pharmacological Sciences, 129, 1-8. https://doi.org/10.1016/j.jphs.2015.02.003
- Zhang, Y., et al. (2019) YiQiFuMai Powder Injection Ameliorates Chronic Heart Failure through Cross-Talk Between Adipose Tissue and Cardiomyocytes via up-Regulation of Circulating Adipokine Omentin. Biomedicine & Pharmacotherapy, 119, Article ID: 109418. https://doi.org/10.1016/j.biopha.2019.109418
- Zhang, Y., et al. (2019) YiQiFuMai Powder Injection Attenuates Coronary Artery Ligation-Induced Heart Failure Through Improving Mitochondrial Function via Regulating ROS Generation and CaMKII Signaling Pathways. Frontiers in Pharmacology, 10, 381. https://doi.org/10.3389/fphar.2019.00381
- Li, S., et al. (2019) Perindopril and a Galectin-3 Inhibitor Improve Ischemic Heart Failure in Rabbits by Reducing Gal-3 Expression and Myocardial Fibrosis. Frontiers in Physiology, 10, 267. https://doi.org/10.3389/fphys.2019.00267